Biotest Facility

Executive Summary

Biotest Facility is a Danish contract research organization (CRO) founded in 2015 and based in Copenhagen. The company specializes in biomarker discovery and validation, offering high-multiplex laboratory testing and analytical services for DNA, RNA, and protein analysis. Its client base spans biotech, pharmaceutical, and academic research organizations, providing end-to-end support from project planning through data analysis. By leveraging advanced multiplex technologies, Biotest Facility enables efficient and comprehensive biomarker profiling, which is critical for drug development and precision medicine. The company operates in the competitive CRO market with a focus on high-value, specialized services that differentiate it from generalist labs. Despite being a small private entity with limited public information, Biotest Facility is positioned to benefit from the growing demand for outsourced biomarker analysis in Europe. The company has not disclosed funding or valuation, suggesting a bootstrapped or early-stage business model. Its low online profile indicates limited market visibility, but its niche expertise in high-multiplex assays could attract strategic partnerships or acquisition interest from larger diagnostic firms. The company's location in a strong life science hub like Copenhagen provides access to talent and collaboration opportunities. However, its micro-cap size and lack of commercial products mean it relies heavily on service contracts, making revenue stream volatile.

Upcoming Catalysts (preview)

• Q4 2026Major contract win with top pharma client50% success
• Q2 2027Launch of new high-multiplex protein analysis platform60% success
• Q3 2026Strategic partnership with diagnostic device company40% success